Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type |Pathology location|Pathology Description|
17-6-1|n/a,n/a|Sequence:1, Age:450,Type:X-rays whole body,Quantity:11.4,Unit:grays,Application:External exposure local, Remarks:upper body =72% of bone marrow, dogs aged 12-17 months|6 (0 in ERA)|Dog|Dog, Beagle|Both|Young Adult|haematological parameters, bone marrow GM-CFC, CFU-F serum CSA sequential studies over one year after second exposure|No information on individuals available for this study
17-6-1|n/a,n/a|Sequence:2, Age:506,Type:X-rays whole body,Quantity:11.7,Unit:grays,Application:External exposure local, Remarks:interval 56 days, lower body (28% of bone marrow) dogs aged 12-17 months|6 (0 in ERA)|Dog|Dog, Beagle|Both|Young Adult|haematological parameters, bone marrow GM-CFC, CFU-F serum CSA sequential studies over one year after second exposure|No information on individuals available for this study
		
